BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 18805579)

  • 41. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
    Rubin CM; Mick R; Johnson FL
    Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.
    De Vita S; Canzonetta C; Mulligan C; Delom F; Groet J; Baldo C; Vanes L; Dagna-Bricarelli F; Hoischen A; Veltman J; Fisher EM; Tybulewicz VL; Nizetic D
    Oncogene; 2010 Nov; 29(46):6102-14. PubMed ID: 20697343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
    Vyas P; Roberts I
    Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
    Kim IS; Park ES; Lim JY; Ki CS; Chi HS
    J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occuring in children with Down syndrome.
    Lanza C; Volpe G; Basso G; Gottardi E; Perfetto F; Cilli V; Spinelli M; Ricotti E; Guerrasio A; Madon E; Saglio G
    Leukemia; 1997 Jun; 11(6):820-1. PubMed ID: 9177434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.
    Kojima S; Matsuyama T; Sato T; Horibe K; Konishi S; Tsuchida M; Hayashi Y; Kigasawa H; Akiyama Y; Okamura J
    Blood; 1990 Dec; 76(11):2348-53. PubMed ID: 2147864
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
    Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
    Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term prognosis of children with Down's syndrome and leukaemia: a 34-year nation-wide experience.
    Rajantie J; Siimes MA
    J Intellect Disabil Res; 2003 Nov; 47(Pt 8):617-21. PubMed ID: 14641809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Down's syndrome and acute megakaryoblastic leukaemia. Case report and review of the literature.
    Lewis DS; Thompson M; Hudson E; Liberman MM; Samson D
    Acta Haematol; 1983; 70(4):236-42. PubMed ID: 6226169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
    Downes CEJ; Rehn J; Heatley SL; Yeung D; McClure BJ; White DL
    Br J Haematol; 2022 Feb; 196(3):700-705. PubMed ID: 34697799
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome.
    Lange B
    Br J Haematol; 2000 Sep; 110(3):512-24. PubMed ID: 10997960
    [No Abstract]   [Full Text] [Related]  

  • 53. Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.
    Blair CK; Roesler M; Xie Y; Gamis AS; Olshan AF; Heerema NA; Robison LL; Ross JA;
    Paediatr Perinat Epidemiol; 2008 May; 22(3):288-95. PubMed ID: 18426524
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GATA1 mutation analysis and molecular landscape characterization in acute myeloid leukemia with trisomy 21 in pediatric patients.
    Panferova A; Gaskova M; Nikitin E; Baryshev P; Timofeeva N; Kazakova A; Matveev V; Mikhailova E; Popov A; Kalinina I; Hachatrian L; Maschan A; Maschan M; Novichkova G; Olshanskaya Y
    Int J Lab Hematol; 2021 Aug; 43(4):713-723. PubMed ID: 33386779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. "TAM"ing of the shrew-challenges in the diagnosis of Neonatal leukemia with Down's syndrome -A case report with literature review.
    Manohar S; Jayakumar N
    Indian J Pathol Microbiol; 2022; 65(3):699-701. PubMed ID: 35900507
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group.
    Dördelmann M; Schrappe M; Reiter A; Zimmermann M; Graf N; Schott G; Lampert F; Harbott J; Niemeyer C; Ritter J; Dörffel W; Nessler G; Kühl J; Riehm H
    Leukemia; 1998 May; 12(5):645-51. PubMed ID: 9593260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.
    Blink M; Buitenkamp TD; van den Heuvel-Eibrink MM; Danen-van Oorschot AA; de Haas V; Reinhardt D; Klusmann JH; Zimmermann M; Devidas M; Carroll AJ; Basso G; Pession A; Hasle H; Pieters R; Rabin KR; Izraeli S; Zwaan CM
    Leukemia; 2011 Aug; 25(8):1365-8. PubMed ID: 21537335
    [No Abstract]   [Full Text] [Related]  

  • 58. Acute leukemia in children with Down's syndrome: the importance of population based study.
    James R; Lightfoot T; Simpson J; Moorman AV; Roman E; Kinsey S;
    Haematologica; 2008 Aug; 93(8):1262-3. PubMed ID: 18519512
    [No Abstract]   [Full Text] [Related]  

  • 59. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
    Hasle H; Kline RM; Kjeldsen E; Nik-Abdul-Rashid NF; Bhojwani D; Verboon JM; DiTroia SP; Chao KR; Raaschou-Jensen K; Palle J; Zwaan CM; Nyvold CG; Sankaran VG; Cantor AB
    Blood; 2022 May; 139(21):3159-3165. PubMed ID: 34758059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
    Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
    Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.